Ionis Pharmaceuticals Inc (IONS) Expected to Post Earnings of $0.56 Per Share

Share on StockTwits

Equities research analysts expect that Ionis Pharmaceuticals Inc (NASDAQ:IONS) will report earnings per share of $0.56 for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Ionis Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.39) and the highest estimate coming in at $1.05. Ionis Pharmaceuticals reported earnings of ($0.01) per share in the same quarter last year, which suggests a positive year over year growth rate of 5,700%. The business is scheduled to announce its next quarterly earnings report on Friday, May 3rd.

According to Zacks, analysts expect that Ionis Pharmaceuticals will report full year earnings of ($0.06) per share for the current financial year, with EPS estimates ranging from ($0.74) to $0.80. For the next financial year, analysts expect that the company will post earnings of $0.89 per share, with EPS estimates ranging from ($0.79) to $4.50. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that cover Ionis Pharmaceuticals.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings results on Wednesday, February 27th. The company reported $2.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $2.20. Ionis Pharmaceuticals had a return on equity of 41.89% and a net margin of 45.64%. The firm had revenue of $192.00 million for the quarter, compared to analyst estimates of $159.59 million. During the same period last year, the company earned ($0.03) EPS. The firm’s quarterly revenue was up 14.3% on a year-over-year basis.

A number of brokerages have issued reports on IONS. ValuEngine raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday. Piper Jaffray Companies set a $63.00 price objective on Ionis Pharmaceuticals and gave the company a “hold” rating in a research note on Friday, March 1st. Zacks Investment Research raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $58.00 price objective on the stock in a research note on Wednesday, January 2nd. Morgan Stanley set a $71.00 price objective on Ionis Pharmaceuticals and gave the company a “hold” rating in a research note on Friday, March 1st. Finally, Leerink Swann assumed coverage on Ionis Pharmaceuticals in a research note on Tuesday, November 27th. They issued a “market perform” rating and a $50.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $60.57.

In related news, SVP Patrick R. O’neil sold 4,400 shares of the business’s stock in a transaction that occurred on Thursday, January 3rd. The stock was sold at an average price of $54.80, for a total transaction of $241,120.00. Following the transaction, the senior vice president now directly owns 14,584 shares of the company’s stock, valued at approximately $799,203.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Richard S. Geary sold 999 shares of the business’s stock in a transaction that occurred on Wednesday, February 13th. The stock was sold at an average price of $60.00, for a total value of $59,940.00. Following the transaction, the senior vice president now directly owns 21,442 shares in the company, valued at $1,286,520. The disclosure for this sale can be found here. Insiders sold a total of 205,660 shares of company stock worth $12,739,354 over the last ninety days. Corporate insiders own 2.44% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Capital Investment Advisory Services LLC acquired a new position in Ionis Pharmaceuticals during the 4th quarter worth approximately $91,000. Hanseatic Management Services Inc. purchased a new stake in Ionis Pharmaceuticals during the 4th quarter worth approximately $440,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Ionis Pharmaceuticals by 82.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,709 shares of the company’s stock worth $957,000 after purchasing an additional 8,014 shares during the last quarter. Bank of Montreal Can increased its holdings in Ionis Pharmaceuticals by 95.2% during the 4th quarter. Bank of Montreal Can now owns 35,651 shares of the company’s stock worth $1,928,000 after purchasing an additional 17,386 shares during the last quarter. Finally, Janney Montgomery Scott LLC increased its holdings in Ionis Pharmaceuticals by 1.1% during the 4th quarter. Janney Montgomery Scott LLC now owns 51,696 shares of the company’s stock worth $2,795,000 after purchasing an additional 554 shares during the last quarter. 84.84% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:IONS traded up $1.10 during mid-day trading on Friday, reaching $78.54. The company’s stock had a trading volume of 1,287,821 shares, compared to its average volume of 995,341. The company has a current ratio of 7.88, a quick ratio of 7.85 and a debt-to-equity ratio of 0.53. Ionis Pharmaceuticals has a twelve month low of $39.07 and a twelve month high of $78.59. The firm has a market cap of $10.60 billion, a price-to-earnings ratio of 26.53 and a beta of 2.40.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Read More: Certificate of Deposit (CD)

Get a free copy of the Zacks research report on Ionis Pharmaceuticals (IONS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply